A structure of an asymmetric supercapacitor and a preparation method thereof is disclosed. In some implementations, the preparation comprises the steps of forming a polyaniline (PANI) nanowire on carbon cloth (CC) substrate (PANI/CC) by polymerization of an aniline, depositing a cobalt-nickel layer double hydroxides (CoNi-LDHs) on the PANI/CC by a hydrothermal process, and calcining of the cobalt-nickel layer double hydroxides (CoNi-LDHs) in the PANI/CC at a high temperature to form a metal carbide (CoC@NiC) on the carbon cloth. The structure of the asymmetric supercapacitor includes a metal carbide (CoC@NiC) as a positive electrode, a tungsten trioxide (WO3@C) as a negative electrode, and a poly (vinyl alcohol)/Potassium hydroxide (PVA/KOH) as an electrolyte gel.
The present disclosure provides a method for biomarker analysis. More particularly, provided herein is a method for identifying biomarker(s) associated with mental health disorder(s) such as but not limited to Major Depressive Disorder (MDD). The said method of the present disclosure is based on an integrative analysis between machine learning and bioinformatics techniques. The method allows efficient mining of publicly available datasets pertaining to mental health disorder patients to identify biomarkers that can aid in the diagnosis and prediction of the onset of such mental health disorders. Further envisaged herein are the biomarker(s) identified by the said method which allow early and efficient detection of mental health disorder(s) by non-invasive methods and application(s) of such biomarker(s).
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16B 25/20 - Réaction en chaîne par polyméraseConception d’amorces ou de sondesOptimisation de la sonde
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
4.
Yeast (S. cerevisiae) sheathing through electrochemical discharge of Cobalt air battery
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
An aptamer-based biosensor for detecting SARS-COV-2 in symptomatic and asymptomatic patients capable of onsite testing of large-scale population of up to 96 people at once providing fast and reliable results. The present invention relates to a novel aptamer-based biosensor for the rapid and reliable detection of SARS-COV-2 viral proteins in nasopharyngeal swabs of suspected individuals with COVID-19.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
6.
PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS
Novel pyridopyridine derivative compounds, methods of preparing the compounds, pharmaceutical compositions comprising one or more such compounds, and methods of treatment of diseases associated with protein kinases.
The invention discloses a thermal management device for high heat flux application in a microelectronic device comprising an integrated board, a microelectronic chip, a thermal interface materials component, a microchannel heat sink assembly operatively connected to the thermal interface materials component, for heat dissipation from the integrated board and the microelectronic chip to the thermal interface materials component, wherein the microchannel heat sink assembly comprises a housing and an adiabatic wall configured to allow heat to pass across the microchannel heat sink assembly. The microchannel heat sink assembly is a four-compartment microchannel heat sink assembly with symmetrical areas.
H01L 23/473 - Dispositions pour le refroidissement, le chauffage, la ventilation ou la compensation de la température impliquant le transfert de chaleur par des fluides en circulation par une circulation de liquides
H01L 21/48 - Fabrication ou traitement de parties, p. ex. de conteneurs, avant l'assemblage des dispositifs, en utilisant des procédés non couverts par l'un uniquement des groupes ou
H01L 23/00 - Détails de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide
8.
Particle-based energy dissipation device for structures
An energy dissipation device is disclosed. The device includes a container, where the container includes a top plate that is horizontally slotted on the container. In addition, the device includes at least one movable plate is inserted through a slot inside the container, and at least two holes inserted in the at least one movable plate. Moreover, the device includes at least two rods partially threaded at both sides of the container. In some implementations, the device may include a frame. In addition, the device includes a damper fixed inside the frame, and a plurality of braces installed in the frame to provide support to the damper. Moreover, the device includes at least one beam and at least one horizontal plate fixed to a bottom face of the at least one beam. A method of assembling an energy dissipation device is also disclosed.
E04H 9/02 - Bâtiments, groupes de bâtiments ou abris conçus pour résister à des situations extérieures anormales, p. ex. à des bombardements, à des séismes ou à des climats extrêmes, ou pour se protéger de ces situations résistant aux séismes ou à l'effondrement du sol
E04B 1/36 - Appuis ou autres supports permettant le mouvement
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
10.
NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2
Novel SARS-CoV-2 inhibitors with dual targeting activity against both the viral RdRp and Mpro and host TMPRSS2 protease for therapeutic formulations and methods for treating SARS-CoV-2 infections. The present disclosure, in some embodiments, provides novel compounds with dual targeting activity against SARS-CoV-2. The compounds selectively target the viral RdRp and Mpro enzymes and host TMPRSS2 protease.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 31/14 - Antiviraux pour le traitement des virus ARN
11.
AUTONOMOUS KNOWLEDGE-BASED SMART WASTE COLLECTION SYSTEM
The present invention relates to a smart knowledge-based waste collection system and method for monitoring and collecting waste of an area by optimizing a dynamic waste collection route by analyzing actual and historical waste generation data of the waste bin to forecast volume of daily waste generated, prioritizing the waste bin to be serviced if a volume of daily waste of the waste bin predicted is larger than bin capacity, assigning waste bin and real-time traffic data to the route optimization module to compute the dynamic waste collection route and transmitting the optimized route to the autonomous vehicle to collect the waste from the waste bins to be serviced.
G06Q 10/30 - Administration du recyclage ou de l’élimination des produits
G01C 21/34 - Recherche d'itinéraireGuidage en matière d'itinéraire
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
12.
Integrated thermal management system with a symmetrical supercapacitor cell
A symmetrical supercapacitor cell is disclosed comprising at least two electrode split sections, at least two electrodes, a plurality of ring isolators, and a spring pin arrangement. The at least two electrodes are placed in between the at least two electrode split sections, wherein a plurality of ring isolators is connected with a plurality of bolts to fasten the at least two electrode split sections. Also disclosed is an integrated thermal management system with a supercapacitor cell including a base support holder, a heating coil casing, a heating coil, and a cavity. The heating coil is installed inside the heating coil casing that is underneath a supercapacitor cell body. Further, a cavity is formed around the supercapacitor cell and contains an oil that is heated via the installed heating coil to achieve a desired temperature.
H01G 11/18 - Agencements ou procédés de réglage ou de protection des condensateurs hybrides ou EDL contre les surcharges thermiques, p. ex. chauffage, réfrigération ou ventilation
H01G 11/28 - Électrodes caractérisées par leur structure, p. ex. multicouches, selon la porosité ou les caractéristiques de surface agencées ou disposées sur un collecteur de courantCouches ou phases entre les électrodes et les collecteurs de courant, p. ex. adhésifs
13.
ENERGY DISSIPATION DEVICE FOR STRUCTURES AND EQUIPMENT
The present disclosure relates to an energy dissipation device and system, comprising a hollow cylinder adapted to be filled with solid balls, and a longitudinal member/shaft having short rods protruding radially therefrom. The shaft having rods is movably disposed of within the hollow member and solid balls are filled and secured in the cylinder thereafter, such that two ends of the longitudinal member extend outside of the hollow member, and the rods and solid balls remain within the hollow cylinder. The ends of the device may be configured with structures or equipment. The movement of the shaft along a longitudinal axis of the cylinder, upon receiving an energy impact in an event of seismic activity, wind loads, and/or man-made vibrations, results in friction between the solid balls and the rods of the shaft, which facilitates dissipation of the received energy.
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
F16F 7/01 - Amortisseurs de vibrationsAmortisseurs de chocs utilisant la friction entre des particules libres, p. ex. du sable
14.
DCT-based watermarking scheme for deep neural networks
The invention discloses a DNN watermarking method, comprising embedding part of the digital watermark in selected redundant elements of a deep neural network (DNN) model—without compromising the performance of the DNN. The proposed method aims for a robust watermark scheme by embedding a large watermark that can span the whole DNN model. If an adversary attempts to destroy the watermark, the whole DNN model will be destroyed. However, maximizing the hiding capacity can lead to degradation in the performance of the DNN model. In this work, this capacity-performance trade-off problem is solved using the Discrete Cosine Transform (DCT). Moreover, the DCT can work more efficiently with highly correlated data. Therefore, this work suggests segmenting the weights of the DNN model into correlated segments to fully exploit the advantages of the DCT.
G06F 21/16 - Traçabilité de programme ou de contenu, p. ex. par filigranage
15.
Prevention, Prophylactic and Therapeutic Treatment of Autoimmune Diseases Including Multiple Sclerosis Using Novel Small Molecules and Compositions Thereof
The present invention relates to the prevention, prophylactic and therapeutic treatment of autoimmune diseases including but not limited to multiple sclerosis by administering novel small molecules to a subject in need thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
This invention relates to a method (30) and system (10) for evaluating circuit protection of a power network. The method (30) includes simulating (32) a multisource, interconnected power network (40) comprising circuit protection elements (A, B, C, D), setting (33) circuit protection element parameters for each circuit protection element, simulating (35) at least one fault (42) on the power network (40) at a predetermined fault position for a predefined simulation time. In a next step, the method includes calculating (38) conductor LTE exposure and determining (39) an LTE threshold. Furthermore, the method (30) includes simultaneously graphically representing (41) a three-dimensional visualisation of the conductor LTE exposure (50) for the predefined simulation time and the LTE threshold (51), on the same three-dimensional visualisation. The method provides a wholistic approach for simulating and determining a dynamic effect of faults for chosen circuit protection settings on conductor LTE exposure compared to LTE thresholds.
G06F 30/367 - Vérification de la conception, p. ex. par simulation, programme de simulation avec emphase de circuit intégré [SPICE], méthodes directes ou de relaxation
17.
BIOMARKERS FOR CEREBRAL METABOLIC DISORDERS, AND DIAGNOSTIC METHODS USING THEREOF
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
UNIVERSITY OF SHARJAH (Émirats arabes unis)
Inventeur(s)
Mabondzo, Aloïse
Broca-Brisson, Léa
Costa, Narciso
Guyot, Anne-Cécile
Armengaud, Jean
Hamoudi, Rifat
Harati, Rania
Abrégé
The disclosure relates to a method for diagnosing a cerebral creatine deficiency syndrome, the method comprising the steps of a) measuring an amount of at least one protein selected from BDNF, KIF1 A, MeCP2, PLCB1, and a combination thereof, in an isolated biological sample, and b) comparing the measured amount obtained at step a) with a predetermined reference amount of said protein, where a difference between the measured amount and the predetermined reference amount is indicative of a cerebral creatine deficiency syndrome in said individual. The disclosure also relates to at least one protein selected from BDNF, KIF1A, MeCP2, PLCB1, and a combination thereof, as a biomarker for use in a method for diagnosing a cerebral creatine deficiency syndrome.
G01N 33/70 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir la créatine ou la créatinine
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
18.
Smart information recognition for user health identification through COVID-19 applications
A system and a method for smart information recognition for user health identification are disclosed. The system and the method comprise a display unit, a color code detection unit, an image filter, an optical character recognition unit, a code detection unit and an elimination unit. The display unit contains a user information. The color code detection unit is associated with the display unit to split at least one of the user information by analyzing at least three colors in an image. The image filter detects at least one of the user's information. Further, the optical character recognition unit recognizes a text of the user information. The code detection unit detects an image code and the elimination unit is used for eliminating a binary object that is close to an image border. The proposed system and method ensure complete security to prevent abuse of an individual's personal information.
G06V 30/224 - Reconnaissance de caractères caractérisés par le type d’écriture de caractères imprimés pourvus de marques de codage additionnelles ou de marques de codage
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G06V 30/18 - Extraction d’éléments ou de caractéristiques de l’image
19.
4N particles in nitrogen-doped carbon nanosheets for hybrid supercapacitors
The present disclosure provides a cooling system facilitating thermal management in a solar photovoltaic (PV) module. The cooling system includes an exhaust fan, operatively coupled to an outlet of a central air conditioning module, the outlet carries waste air from the central air conditioning module. A supporting structure is placed at a predefined distance in front of the exhaust fan to support one or more solar panels. The one or more solar panels are tilted at a predefined angle and a predefined azimuth configured to provide maximum surface area of the back units of the one or more solar panels. The exhaust fan is further configured to direct the waste air and surrounding air towards the back units of the one or more solar panels at a predefined temperature.
H01G 11/30 - Électrodes caractérisées par leur matériau
H01G 11/86 - Procédés de fabrication de condensateurs hybrides ou EDL ou de leurs composants spécialement adaptés pour les électrodes
H01G 11/24 - Électrodes caractérisées par les propriétés structurelles des matériaux composant les électrodes ou inclus dans les électrodes, p. ex. forme, surface ou porositéÉlectrodes caractérisées par les propriétés structurelles des poudres ou particules utilisées à cet effet
Provided is a fixture for automatic assembly, overturning and welding of sidewall aluminum profile of a rail vehicle, comprising a lifting mechanism, a supporting overturning device mounted on the lifting mechanism, an automatic assembling sidewall profile device mounted on the supporting overturning device, and a self-positioning locking device. The automatic assembling sidewall profile device comprises a sidewall-shaped support steel beam, and a rodless cylinder track platform and a fixing seat. The self-positioning locking devices are mounted on the rodless cylinder track platform and the fixing seat, and have a self-positioning base and a locking device. The self-positioning base comprises an outer housing is provided with the locking device and two symmetrically set self-positioning supports, and faces of the two self-positioning supports matching with the rail vehicle aluminum profile are provided with rollers having a V-shaped gap formed therebetween.
B23K 37/04 - Dispositifs ou procédés auxiliaires non spécialement adaptés à un procédé couvert par un seul des autres groupes principaux de la présente sous-classe pour maintenir ou mettre en position les pièces
B23K 101/00 - Objets fabriqués par brasage, soudage ou découpage
B23K 37/00 - Dispositifs ou procédés auxiliaires non spécialement adaptés à un procédé couvert par un seul des autres groupes principaux de la présente sous-classe
23.
Full-automatic wheel hub three-dimensional scanning system for intelligent production lines of automotive wheel hub
Provided a full-automatic wheel hub 3D scanning system for intelligent production line of automotive wheel hubs, comprising: a base plate is provided with an X-directional displacement control device and a Y-directional displacement control device; a roller-table assembly is arranged on the base plate and comprises a roller table, wherein the roller table is provided with an opposite-type photoelectric sensors and a wheel hub centring positioning device for centring positioning a wheel hub; a 3D scanning device, comprising a mounting bracket, wherein the bottom of the mounting bracket is controlled by the Y-directional displacement control device; a 3D scanner is mounted on the mounting bracket; a wheel hub scanning platform is arranged at an end of the roller-table assembly and is controlled by the X-directional displacement control device; and a robot is arranged on a first side of the wheel hub scanning platform, for conveying the wheel hubs after 3D scanning.
An apparatus for thaw detection of a frozen item is disclosed, the apparatus comprising a housing container comprising a first transparent section and a second opaque section, at least one low density floating object and at least one high density object both encased within the housing container, wherein the housing container is filled with a filling mixture and melting of the filling mixture results in the at least one low density floating object and at least one high density object to be visible in the first transparent section of the housing container, thereby enabling thaw detection of the frozen item. Also disclosed is a method of manufacturing an apparatus for thaw detection of a frozen item.
G01K 11/06 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant la fusion, la congélation ou le ramollissement
25.
Anti-SARS CoV-2 inhibitors by dual viral-host targeting
The present invention discloses novel SARS-CoV-2 inhibitors for therapeutic formulations and methods for treating SARS-CoV-2 infections. The compounds exhibit unique pharmacophoric features including conformational flexibility and spatial orientation within the binding sites of the targeted proteases. The present invention also discloses methods for treating SARS-CoV-2 infections, comprising administering to the subject in need thereof a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical excipients.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
26.
DISCOVERY OF ANTI-SARS-COV-2 INHIBITORS BY DUAL VIRAL-HOST TARGETING
The present invention discloses novel SARS-CoV-2 inhibitors for therapeutic formulations and methods for treating SARS-CoV-2 infections. The compounds exhibit unique pharmacophoric features including conformational flexibility and spatial orientation within the binding sites of the targeted proteases. The present invention also discloses methods for treating SARS-CoV-2 infections, comprising administering to the subject in need thereof a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical excipients.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
27.
Discovery of imidazothiazole- and imidazooxazole-based selective HER4 kinase inhibitors as potential anticancer agents
Novel first-in-class imidazothiazole- and imidazooxazole-based potent and selective HER4 kinase inhibitors for therapeutic formulations and methods for treating cancer.
This invention relates to a method (30) and system (10) for evaluating circuit protection of a power network. The method (30) includes simulating (32) a multisource, interconnected power network (40) comprising circuit protection elements (A, B, C, D), setting (33) circuit protection element parameters for each circuit protection element, simulating (35) at least one fault (42) on the power network (40) at a predetermined fault position for a predefined simulation time. In a next step, the method includes calculating (38) conductor LTE exposure and determining (39) an LTE threshold. Furthermore, the method (30) includes simultaneously graphically representing (41) a three-dimensional visualisation of the conductor LTE exposure (50) for the predefined simulation time and the LTE threshold (51), on the same three-dimensional visualisation. The method provides a wholistic approach for simulating and determining a dynamic effect of faults for chosen circuit protection settings on conductor LTE exposure compared to LTE thresholds.
G06F 30/367 - Vérification de la conception, p. ex. par simulation, programme de simulation avec emphase de circuit intégré [SPICE], méthodes directes ou de relaxation
G06F 30/31 - Saisie informatique, p. ex. éditeurs spécifiquement adaptés à la conception de circuits
G06F 119/02 - Analyse de fiabilité ou optimisation de fiabilitéAnalyse de défaillance, p. ex. performance dans le pire scénario, analyse du mode de défaillance et de ses effets [FMEA]
G06F 119/06 - Analyse de puissance ou optimisation de puissance
29.
Method of measuring impedance using Gaussian white noise excitation
G01R 27/16 - Mesure de l'impédance d'un élément ou d'un réseau dans lequel passe un courant provenant d'une autre source, p. ex. câble, ligne de transport de l'énergie
G01R 27/04 - Mesure de résistances, de réactances, d'impédances réelles ou complexes, ou autres caractéristiques bipolaires qui en dérivent, p. ex. constante de temps dans des circuits comportant des constantes réparties
30.
Conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment
Novel conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for therapeutic formulations and methods for treating cancer.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
There is provided novel anticancer and antibacterial compounds, pharmaceutically acceptable salts thereof, and processes for their preparation. The compounds have anticancer activity, which results in the reduction of tumour cell proliferation, enhances cancers cells apoptosis and regulation of iron signalling. The compounds are also particularly active against various Gram-negative and Gram-positive multidrug-resistant bacteria, such as extended-spectrum beta-lactamase (ESBL) producing and colistin-resistant Escherichia coli, carbapenem-resistant E. coli, carbapenem-resistant Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA) including those with reduced susceptibility to many control antibiotics.
A compound represented by following formula I:
according to the present disclosure. The disclosed compound is useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for preparations and methods for pharmaceutical applications, for example, as anticancer agents. The compound was found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compound also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, the compound represented by Formula I targets multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.
C07D 471/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 491/147 - Systèmes condensés en ortho le système condensé contenant un cycle avec l'oxygène comme hétéro-atome du cycle et deux cycles avec l'azote comme hétéro-atome du cycle
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
34.
A SOLAR PHOTOVOLTAIC PANEL FOG/MIST COOLING SYSTEM
The application discloses a solar photovoltaic panel fog/mist cooling system which comprises at least one solar photovoltaic panel (101), and at least one nozzle (110) arranged at a back side of the at least one solar photovoltaic panel (101) and configured to generate a fog/mist applied onto a back side of the at least one solar photovoltaic panel (101).
F24S 40/55 - Agencements pour le refroidissement, p. ex. en utilisant des moyens externes de dissipation de la chaleur ou par circuits de refroidissement internes
There is provided a solar photovoltaic panel fog/mist cooling system which comprises at least one solar photovoltaic panel, and at least one nozzle arranged at a back side of the at least one solar photovoltaic panel and configured to generate a fog/mist applied onto a back side of the at least one solar photovoltaic panel.
F25B 19/04 - Machines, installations ou systèmes utilisant l'évaporation d'un frigorigène mais sans récupération de vapeur utilisant un jet fluide, p. ex. de vapeur utilisant un jet liquide, p. ex. d'eau
36.
Small molecule inhibitors of fungal hyphae and biofilm formation
Novel compounds having inhibitory activity on the formation of fungal hyphae and biofilms, and therapeutic formulations and methods based on the novel inhibitors.
Novel compounds having inhibitory activity on the formation of fungal hyphae and biofilms, and therapeutic formulations and methods based on the novel inhibitors.
The invention provides an identification system for ascertaining who is at risk of haying or already has asthma or severe asthma. The system is based upon transcriptomic expression data from RNA extracted from saliva, blood, sputum, bronchial brush, and biopsies samples as well as optionally demographic, risk factor, and symptom data. Also provided are related materials and methods, including such as primers and kits.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
39.
DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA
The invention provides an identification system for ascertaining who is at risk of having or already has asthma or severe asthma. The system is based upon transcriptomic expression data from RNA extracted from saliva, blood, sputum, bronchial brush, and biopsies samples as well as optionally demographic, risk factor, and symptom data. Also provided are related materials and methods, including such as primers and kits.
There is provided a needle tip for extracting separated endodontic instruments from the root canal of a tooth. The needle tip is fabricated with a thermomechanically treated alloy exhibiting both shape memory and super-elasticity. There is also provided for a needle that includes a handle and a terminal tip, which is fabricated with a thermomechanically treated alloy. The alloy is thermomechanically treated nickel- titanium alloy. The needle is straight at room temperature and takes on a specific shape when inserted in the canal of the tooth from which the endodontic separated instrument is to be extracted. Also provided herein is a method for removal of endodontic separated instruments from the canal of a tooth.
The present invention relates to novel antitumor agents and pharmaceutically acceptable salts thereof, processes and intermediates for the manufacture of these novel constrained cyclic frameworks of general formula I and II, and medicaments containing such compounds.
C07D 459/00 - Composés hétérocycliques contenant des systèmes cycliques benz [g] indolo [2, 3-a] quinolizine, p. ex. yohimbineLeurs lactones en 16, 18, p. ex. lactone de l'acide réserpique
A61K 31/4738 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/4747 - QuinoléinesIsoquinoléines condensées en spiro
42.
NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL APPLICATIONS THEREOF
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
Novel heterocyclic systems are herein disclosed, which possess many biological activities, including but not limited to anticancer activity. The disclosed compounds are useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for their preparations and methods for their pharmaceutical applications, for example, as anticancer agents. These compounds were found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compounds also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, these novel compounds were able to target multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 31/429 - Thiazoles condensés avec des systèmes hétérocycliques
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
The invention provides atropine sulfate (AS) rapidly-disintegrating sublingual tablets (RDSTs) of improved formulation in a sublingual dosage form and methods for therapeutic use of the AS RDSTs for treatment of organophosphate (OP) exposure and acute toxicity. The AS RDSTs provide an alternative easy-to-use dosage form for the management of organophosphate toxicity. Additionally, the invention provides methods for improved formulation and quality evaluation of the atropine sulfate rapidly-disintegrating sublingual tablets.
A61K 31/4425 - Dérivés de pyridinium, p. ex. pralidoxime, pyridostigmine
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
ATROPINE SULFATE RAPIDLY-DISINTEGRATING SUBLINGUAL TABLETS, METHODS FOR MANUFACTURE THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF ACUTE ORGANOPHOSPHATE TOXICITY
The invention provides atropine sulfate (AS) rapidly-disintegrating sublingual tablets (RDSTs) in a sublingual dosage form and methods for therapeutic use of the AS RDSTs for treatment of organophosphate (OP) exposure and acute toxicity. The AS RDSTs provide an alternative easy-to-use dosage form for the management of organophosphate toxicity. Additionally, the invention provides methods for formulation and quality evaluation of the atropine sulfate rapidly-disintegrating sublingual tablets.
brevets
